Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16561297 | 0.97 | MAPT (0.40) | ALOX5RRM1MAPTALDH1A1KDM4E | |
| SCHEMBL8613770 | 0.92 | RRM1 (0.45) | ALOX5RRM1MAPTALDH1A1KDM4E | |
| Perchlorate SCHEMBL637063 | 0.88 | ALOX5 (0.34) | ALOX5RRM1MAPTALDH1A1KDM4E | |
| SCHEMBL8615984 | 0.86 | RRM1 (0.41) | ALOX5RRM1MAPTALDH1A1KDM4E | |
| SCHEMBL28081794 | 0.86 | CHRM5 (0.43) | ALOX5MAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL635117 | 0.85 | MAPT (0.39) | ALOX5RRM1MAPTALDH1A1KDM4E | |
| SCHEMBL635229 | 0.83 | MEN1 (0.42) | MAPTALDH1A1TDP1MEN1RAB9A | |
| SCHEMBL30894434 | 0.83 | MEN1 (0.42) | MAPTALDH1A1TDP1MEN1RAB9A | |
| SCHEMBL29176 | 0.81 | MAPT (0.39) | RRM1MAPTALDH1A1TDP1MEN1 | |
| SCHEMBL29361524 | 0.81 | MAPT (0.39) | RRM1MAPTALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1927596-B9 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2013-05-15 | — | — | EP | claimed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | claimed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | claimed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | claimed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | claimed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10710989-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-14 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6184415-B1 | ASYMMETRIC HYDROGENATION OF A 2-HALO(ELECTRONEGATIVE)ALKENOIC ACID/SALT (2-HALOACRYLIC ACID OR SALT), USING AN ENANTIOMETRICAL RICHED CATALYST OF 2,2'-BIS(DIARYLPHOSPHINO-PHINO-1,1'-BINAPHTHYL COMPLEX OF RUTHENIUM; HALIDE PROMOTERS | ALBEMARLE CORPORATION | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | ALOX5 234/4885RRM1 610/4885MAPT 3660/4885 |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | ALOX5 3811/4885RRM1 181/4885MAPT 234/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | ALOX5 4542/4885RRM1 290/4885MAPT 4502/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | ALOX5 234/4885RRM1 610/4885MAPT 3660/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | ALOX5 234/4885RRM1 610/4885MAPT 3660/4885 |
| US-10710989-B2 | Method for producing heterocyclic compound | APP, THOP1, TALDO1 | ALOX5 274/4885RRM1 4459/4885MAPT 16/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | ALOX5 1012/4885RRM1 454/4885MAPT 4851/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | ALOX5 234/4885RRM1 610/4885MAPT 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.